𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Progression of liver fibrosis in women infected with hepatitis C: Long-term benefit of estrogen exposure

✍ Scribed by Mical Campbell; Yu-Xiao Yang; K. Rajender Reddy


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
149 KB
Volume
41
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


We read with interest the paper by Di Martino et al. published in the December 2004 issue of HEPATOLOGY 1 that examines estrogen-related effects on hepatitis C fibrosis. Specifically, progression of hepatitis C fibrosis was correlated with prior pregnancies, menopausal status, past use of oral contraceptives, and hormone replacement therapy. Hepatitis C-infected women who completed a survey and had previously undergone liver biopsy were eligible for the study. The investigators calculated a rate of progression of fibrosis, dividing fibrosis stage (in Metavir units) by years of hepatitis C infection. This approach has been used previously in a selfdescribed cross-sectional study. 2 The present study is labeled a "retrospective cohort study," although it would be better characterized as a cross-sectional study. Information from a single survey was correlated with results from a single liver biopsy. Patients were not followed by repeated biopsies or repeated surveys over time.

The distinction between cohort and cross-sectional is not merely semantic in this case. Figures 3 and4 are Kaplan-Meier curves for the development of significant fibrosis in "cohorts" of hepatitis C patients. Kaplan-Meier curves depend on the precise knowledge of when a patient in a cohort develops significant fibrosis. For example, a patient with a biopsy showing stage 4 fibrosis and 20 years of disease duration would be plotted on a Kaplan-Meier curve as having developed significant fibrosis (stage 2) after 20 years' disease duration. Without a prior biopsy, it is not known at what time the patient actually developed stage 2 fibrosis. To address the impossibility of accurate censoring, the authors could have back-extrapolated to estimate time to development of stage 2 fibrosis, assuming linear progression of fibrosis. The problem with that approach is that it involves using a calculated result to generate primary data-for re-analysis.

In short, even though the investigators describe a rate of progression of fibrosis, the data do not truly describe a cohort. Statistical methods generally reserved for cohort studies cannot be applied easily to cross-sectional data.


πŸ“œ SIMILAR VOLUMES


Progression of liver fibrosis in women i
✍ Vincent Di Martino; Pascal Lebray; Robert P. Myers; Emmanuelle Pannier; ValΓ©rie πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 173 KB πŸ‘ 1 views

Female sex is a protective factor for the progression of fibrosis in patients with chronic hepatitis C virus (HCV) infection. Experimental data suggest that estrogens may have an antifibrotic effect. The objective of this study was to evaluate the influence of past pregnancies, oral contraceptives,

Steatosis and progression of fibrosis in
✍ Ponni Perumalswami; David E. Kleiner; Glen Lutchman; Theo Heller; Brian Borg; Yo πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 218 KB πŸ‘ 2 views

Hepatic steatosis is common in patients with chronic hepatitis C (CHC) and is reported to be a risk factor for progression of fibrosis. The aims of this study were to evaluate the interactions between hepatic steatosis and fibrosis in a well-defined cohort of patients with CHC. The computerized path

Long-term histological effects of preemp
✍ Alexander Kuo; Vivian Tan; Billy Lan; Mandana Khalili; Sandy Feng; John P. Rober πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 197 KB

The long-term effects of preemptive antiviral therapy on fibrosis progression in liver transplant recipients with hepatitis C virus (HCV) were examined in a cohort of consecutive liver transplant recipients who received preemptive antiviral therapy for 48 weeks (95% were virologic nonresponders). Co

A prospective evaluation of fibrosis pro
✍ Nevin Yilmaz; Mitchell L. Shiffman; R. Todd Stravitz; Richard K. Sterling; Velim πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 186 KB πŸ‘ 2 views

Recurrence of hepatitis C virus (HCV) following liver transplantation (LT) is universal. A subset of these patients develop advanced fibrosis and cirrhosis and it is believed that this leads to increased posttransplantation mortality. The specific aims of this study were to determine the incidence o

Liver stiffness identifies two different
✍ JosΓ© A. CarriΓ³n; Ferran Torres; Gonzalo Crespo; Rosa Miquel; Juan-Carlos GarcΓ­a- πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 611 KB

Significant liver fibrosis (F >or= 2) and portal hypertension (hepatic venous pressure gradient [HVPG] >or= 6 mmHg) at 1 year after liver transplantation (LT) identify patients with severe hepatitis C recurrence. We evaluated whether repeated liver stiffness measurements (LSM) following LT can discr

Long-term evolution of fibrosis from chr
✍ M Kage; K Shimamatu; E Nakashima; M Kojiro; O Inoue; M Yano πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 177 KB πŸ‘ 2 views

atitis activity index scoring system 14 and others, [15][16][17] have To clarify the characteristics of fibrosis developed in been used in the assessment of the degree of fibrosis, howthe process from chronic hepatitis C to cirrhosis, a morever, these methods cannot completely avoid the observer's p